-
UK set for cautious budget as borrowing costs climb
-
Afghans compete for jobs, homes as millions return
-
Anthropic's record IPO faces some big questions
-
'They don't care about us': Trump food aid cuts leave Americans struggling and angry
-
US Fed expected to hold rates steady ahead of key midterm elections
-
Meta, Snap head to trial in another case about social media's harms
-
Can this Latin Grammy-winner help Democrats win back Congress?
-
French Senate passes bill to make protesters pay for unrest damage
-
Tuvalu has 'limited' power to halt its fossil fuel investments: NZ govt papers seen by AFP
-
India evacuates tens of thousands as Cyclone Arnab makes landfall
-
Palestinian activist Khalil returns to Columbia after US detention
-
In tight Israel vote, both camps hold out cautious hope
-
Trump drastically loosens oil and gas methane rules
-
AI chip giant SK hynix says quarterly operating profit soars 630%
-
French Senate weighs bill to make protesters pay for unrest damage
-
Youths testify about 'despair' in unprecedented Canadian climate trial
-
'A very sad day': Arteta despair as Arsenal stunned by Fleetwood
-
Syria, Jordan agree to mend ties after deadly strike
-
Charles tackles thorny legacy of slavery on Caribbean trip
-
Arsenal stunned by fourth-tier Fleetwood in League Cup
-
Former Grand Slam winner Wawrinka ends tennis career
-
Last-gasp Sabitzer strike sends Dortmund past Bremen in German Cup
-
Brazil's Flavio Bolsonaro flees to US after election loss
-
Rights groups reject Emirati diplomat for UN top job
-
'Faerie' nights: 'ACOTAR' fans finally get their book
-
Flavio Bolsonaro headed to US after Brazil election defeat: US media
-
American woman convicted of getting military training from Islamic State
-
Alcaraz and Zverev win Vienna openers
-
Israel opposition holds narrow edge over Netanyahu in first projections
-
Tech firms gain ahead of Fed decision, results from AI giants
-
Floriani hits maiden goal as Lazio go top
-
Syria condemns deadly Jordan strikes as 'unacceptable violation'
-
Trump set to drastically loosen oil and gas sector's methane rules
-
England's Fin Smith in race against time to face Australia
-
Storied Paris department store seeks bankruptcy protection
-
UN nuclear watchdog chief urges Iran to grant access
-
Xhaka, Embolo can return to Swiss squad after fake Covid docs affair
-
Boeing shares tumble after it releases cautious growth forecast
-
Allegri suspended for two Serie A games after red card
-
Lula's re-election revives Brazil-US tensions
-
Flight data, satellite images reveal growing US role at Ecuador base
-
Carney moves to remake Canada alliances as US ties strained
-
McInnes feels 'guilt' ahead of Hearts return with Rangers
-
Serbia's students demand state media chiefs resign after poll win
-
Brazil's Lula turns 81, vows to work '24 hours a day'
-
Starc takes six as Australia fight back in South Africa decider
-
Boeing releases cautious growth plan as shares fall sharply
-
UK man offered drugged wife to strangers online for sex: court
-
Exiled Russian dissident Navalnaya warns dictators becoming 'more cunning'
-
Africa Ebola outbreak passes 10,000 cases, mostly in DR Congo
US study tests psilocybin to fight cancer side effects
Here's a novel idea for countering the painful side effects of chemotherapy: beforehand, take the hallucinogenic drug found in magic mushrooms.
The study published Thursday in the journal Science involved tests on rats and certain human tissues as researchers looked at using psilocybin to fight a condition called peripheral neuropathy, which affects millions of people around the world.
It is a nerve ailment that hits about three quarters of all people who undergo chemo and commonly causes numbness and tingling, Patrick Dougherty, a co-author of the study, said in a call with reporters.
But a third of that group will develop non-stop, burning pain, said Dougherty, a pain treatment specialist at the University of Texas MD Anderson Cancer Center.
The symptoms can lead to trouble walking and other debilitating complications that can last after a person finishes chemotherapy, and even remain with them for life.
And it is not just a quality-of-life issue. This complication also affects a cancer patient's chances of survival because sometimes the side effects are so bad they force doctors to cut back on chemo or stop it altogether.
- Protecting nerves -
It was almost by accident that these researchers found that psilocybin can help cancer patients.
The team was initially studying how the disease manages to hijack nerve cells in order to grow.
And the researchers were surprised to see the mushroom ingredient -- it was being used to study a brain pathway regeneration concept called neuroplasticity -- actually prevented the emergence of peripheral neuropathy.
Later experiments highlighted psilocybin's role in protecting nerve cells and stimulating inside them the transport of mitochondria, often referred to as a cell's powerhouse.
This is key because chemo destroys the microscopic railroads that allow mitochondria to send energy all the way to the tips of people's hands and feet, killing off nerve endings there.
Psilocybin also seems to act on the brain, preserving electrical activity that chemotherapy thwarts.
In rodents, taking two doses of psilocybin before chemo was enough to prevent the appearance of painful hypersensitivity during as many as six rounds of treatment. And it did this without affecting the animal's immune system or hindering the cancer-fighting action.
- Careful with self-medicating -
"This is a highly promising finding," said Kristy Townsend, a professor of neurobiology at The Ohio State University who was not involved in the study.
And psilocybin's nerve-protecting quality does not seem to be linked to its hallucinogenic effects because a non-hallucinogenic analogue had the same effect in a lab test, she added.
Before the treatment can be made standard for people, testing will be needed to see if it is safe and effective, said Townsend.
This will be a long, slow process though it should be eased by a boom in medical research on psychedelic substances and a Trump administration executive order in April to speed up research and regulatory reviews, these scientists say.
The MD Anderson Cancer Center plans to launch clinical tests with psilocybin on cancer patients later this year.
Meanwhile it is important for cancer patients to avoid using magic mushrooms on their own as treatment, the researchers warned.
Psilocybin is legal in a few US states.
The drug has an "amplifier" effect and cancer patients who take it without supervision could feel more stressed and anxious than they already are because of their cancer diagnosis, said Gregory Jones, a psychiatrist who took part in the study released Thursday.
"If you put somebody in adversity under these psychedelic substances, you can get much worse," Jones said.
C.Kreuzer--VB